BPC-157 and TB-500 are the two most discussed peptides in the biohacking and sports medicine communities. They are routinely combined into what vendors call the "Wolverine Stack" and marketed as a recovery protocol for tendon injuries, muscle tears, and ligament damage. Neither compound has a single published, controlled human trial for musculoskeletal repair.
That is not a minor caveat. It is the defining fact of both compounds. Everything else, the mechanism papers, the animal data, the community protocols, exists downstream of that gap. This post breaks down what the evidence actually shows for each compound, where they genuinely differ, and what the honest assessment looks like when you strip away the marketing.
This is the single most important clarification in the entire TB-500 evidence base, and most sources get it wrong. TB4 (Thymosin Beta-4) is the full-length 43-amino-acid endogenous protein. TB-500 is a synthetic 7-amino-acid fragment. Every human clinical trial has used TB4, not TB-500.
TB4 has Phase 2 RCT data in dry eye (three trials, zero adverse events, Phase 3 underway), Phase 2 data in chronic wound healing (42% to 61% improvement over placebo), and a Phase 1 IV safety study in 40 healthy adults tolerating doses up to 1,260 mg with no serious adverse events. This is real, controlled human data.
TB-500, the fragment that people actually buy from research peptide vendors, has zero human clinical trials. None. The assumption that a 7-amino-acid fragment replicates the activity of a 43-amino-acid protein is mechanistically plausible but clinically unvalidated. When someone says "TB-500 has human data," they are attributing TB4's clinical evidence to a different molecule.
BPC-157 has the largest preclinical literature of any research peptide: over 500 published papers spanning GI healing, tendon repair, neuroprotection, and cardiovascular models. The mechanistic picture is coherent and well-characterized: VEGFR2-driven angiogenesis, Akt/eNOS signaling, and NO system modulation create a plausible molecular explanation for the tissue repair effects observed in animal models.
The human evidence base consists of fewer than 30 human subjects across all published studies. A 2025 systematic review in the American Journal of Sports Medicine examined the full BPC-157 literature from an orthopedic perspective and found that human studies amount to small, uncontrolled case reports with no placebo groups.
A Phase 2 trial for inflammatory bowel disease was initiated in 2015 by a Croatian group but results were never published in a peer-reviewed journal. A 2025 pilot study reported IV BPC-157 infusion in two healthy adults up to 20 mg with no adverse events and plasma clearance within 24 hours. That is the complete human pharmacokinetic dataset: two people.
The regulatory status is unambiguous. The FDA placed BPC-157 on the Category 2 bulk drug substance list in 2023, meaning it cannot be commercially compounded for human use. It is sold through unregulated research chemical vendors with no quality standards, no purity guarantees, and no regulatory oversight.
The irony of TB-500's popularity is that its most sought-after application, musculoskeletal and tendon repair, has the weakest evidence of any indication in its profile. The preclinical tendon data is consistent and mechanistically sound: actin cytoskeletal remodeling, progenitor cell mobilization, and integrin-linked kinase signaling all support a tissue repair mechanism. But consistent preclinical data describes many compounds that failed in human trials.
TB4 (the parent compound, not TB-500) has its strongest human evidence in ophthalmology: three Phase 2 RCTs for dry eye and corneal injury with zero adverse events. Phase 3 is underway. The wound healing data from Phase 2 showed wounds healing in 39 days versus 71 days with standard care. These are real results in real humans with the full-length protein.
TB-500 was de-listed by the FDA as a compoundable drug in September 2024 and is prohibited by WADA at all times in all sports. Athletes subject to doping control cannot use it under any circumstances.
The mechanisms are genuinely complementary, not overlapping. BPC-157 operates primarily through VEGFR2-driven angiogenesis: it drives new blood vessel formation to supply healing tissue with blood flow. TB4/TB-500 operates through actin cytoskeletal regulation: it mobilizes cells toward the injury site and organizes the structural scaffold for repair. One builds the roads, the other moves the workers. This is why they are combined: the mechanistic rationale for co-administration is scientifically sound.
What is not sound is the leap from "mechanistically complementary" to "validated combination therapy." No published study has tested BPC-157 and TB-500 together in any model, animal or human. The "Wolverine Stack" is a vendor marketing term, not a research protocol. The synergy is hypothesized, not demonstrated.
BPC-157 human data: fewer than 30 subjects total, no controlled musculoskeletal trials, one IBD Phase 2 (results never published), one IV PK pilot (n=2). FDA Category 2, cannot be compounded. Not WADA prohibited.
TB-500 human data: zero. All human trials used TB4, a different molecule. TB4 has Phase 2 data in ophthalmology and wound healing. TB-500 (the fragment) has no human evidence of any kind. FDA de-listed September 2024. WADA prohibited.
Both compounds: zero human musculoskeletal RCTs. Zero published human data for tendon, ligament, or muscle repair. Zero validated dosing protocols for subcutaneous injection for tissue repair. The entire community dosing framework (BPC-157: 200 to 500 mcg/day, TB-500: 2 to 5 mg twice weekly) is extrapolated from animal studies.
The preclinical data for both compounds is interesting and internally consistent. The mechanistic pathways are well-characterized. The complementary mechanism rationale for combining them is scientifically reasonable. If controlled human musculoskeletal trials were conducted, they might well show efficacy. The biology supports the hypothesis.
But biology supporting a hypothesis is not the same as clinical evidence confirming it. The history of drug development is filled with compounds that had compelling preclinical data and failed in humans. The gap between "works in rats" and "works in people" is the entire reason clinical trials exist.
The honest position is: these are research compounds with promising preclinical profiles, no validated human efficacy data for their most popular applications, and significant regulatory restrictions. Anyone using them is participating in an uncontrolled experiment with unknown risk, using products from unregulated suppliers with unverified purity.
The question is not whether BPC-157 and TB-500 "work." The question is whether anyone has proven they work in humans, at what dose, for what indication, with what safety profile. As of April 2026, the answer to every one of those questions is no.
Complete profiles with all use cases, mechanism deep dives, dosing data, regulatory status, and editorial assessments are available in the database: BPC-157 (free, full profile) and TB-500 (premium). Both profiles include evidence tables, safety analyses, and comparative notes against other compounds in the database.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use